EP2820151 - CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 21.02.2020 Database last updated on 03.09.2024 | |
Former | Grant of patent is intended Status updated on 01.10.2019 | ||
Former | Examination is in progress Status updated on 15.11.2016 | Most recent event Tooltip | 27.04.2024 | Lapse of the patent in a contracting state New state(s): MK | published on 29.05.2024 [2024/22] | Applicant(s) | For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH | [2015/34] |
Former [2015/02] | For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH | ||
For all designated states IRM LLC 131 Front Street P.O. Box HM 2899 Hamilton HM LX / BM | Inventor(s) | 01 /
CONG, Feng Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, MA 02139 / US | 02 /
HAO, Huaixiang Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, MA 02139 / US | 03 /
HSIEH, Hsin-i Genomics Institute of the Novartis Research Foundation 10675 John Jay Hopkins Drive San Diego, CA 92121 / US | 04 /
JIANG, Xiaomo Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, MA 02139 / US | 05 /
LIU, Jun Genomics Institute of the Novartis Research Foundation 10675 John Jay Hopkins Drive San Diego, CA 92121 / US | 06 /
NG, Nicholas Genomics Institute of the Novartis Research Foundation 10675 John Jay Hopkins Drive San Diego, CA 92121 / US | [2020/13] |
Former [2015/02] | 01 /
CONG, Feng Novartis Institutes for Biomedical Research, Inc. 250 Massachusetts Avenue Cambridge, MA 02139 / US | ||
02 /
HAO, Huaixiang Novartis Institutes for Biomedical Research, Inc. 250 Massachusetts Avenue Cambridge, MA 02139 / US | |||
03 /
HSIEH, Hsin-i Genomics Institute of the Novartis Research Foundation 10675 John Jay Hopkins Drive San Diego, CA 92121 / US | |||
04 /
JIANG, Xiaomo Novartis Institutes for Biomedical Research, Inc. 250 Massachusetts Avenue Cambridge, MA 02139 / US | |||
05 /
LIU, Jun Genomics Institute of the Novartis Research Foundation 10675 John Jay Hopkins Drive San Diego, CA 92121 / US | |||
06 /
NG, Nicholas Genomics Institute of the Novartis Research Foundation 10675 John Jay Hopkins Drive San Diego, CA 92121 / US | Representative(s) | Kristl, Jernej, et al Novartis Pharma AG Patent Department 4002 Basel / CH | [2020/13] |
Former [2015/02] | Kristl, Jernej Novartis Pharma AG Patent Department 4002 Basel / CH | Application number, filing date | 13707527.1 | 22.02.2013 | [2020/13] | WO2013US27441 | Priority number, date | US201261604290P | 28.02.2012 Original published format: US 201261604290 P | [2015/02] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2013130364 | Date: | 06.09.2013 | Language: | EN | [2013/36] | Type: | A1 Application with search report | No.: | EP2820151 | Date: | 07.01.2015 | Language: | EN | The application published by WIPO in one of the EPO official languages on 06.09.2013 takes the place of the publication of the European patent application. | [2015/02] | Type: | B1 Patent specification | No.: | EP2820151 | Date: | 25.03.2020 | Language: | EN | [2020/13] | Search report(s) | International search report - published on: | EP | 06.09.2013 | Classification | IPC: | C12Q1/68 | [2015/02] | CPC: |
C12Q1/6886 (EP,CN,RU,US);
G01N33/57438 (RU,US);
C12Q1/68 (KR);
A61K31/497 (EP,RU,US);
A61P1/18 (EP);
A61P35/00 (EP);
A61P43/00 (EP);
G01N33/57492 (RU,US);
C12Q2600/106 (EP,CN,RU,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/02] | Extension states | BA | 29.09.2014 | ME | 29.09.2014 | Title | German: | KREBSPATIENTENAUSWAHL ZUR VERABREICHUNG VON WNT-SIGNALÜBERTRAGUNGSHEMMERN UNTER VERWENDUNG EINER RNF43-STATUS-MUTATION | [2015/02] | English: | CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS | [2015/02] | French: | SÉLECTION DE PATIENTS ATTEINTS D'UN CANCER POUR ADMINISTRER DES INHIBITEURS DE SIGNALISATION DE LA VOIE WNT AU MOYEN DE L'ÉTAT DE MUTATION RNF43 | [2019/44] |
Former [2015/02] | SÉLECTION DE PATIENT ATTEINTS D'UN CANCER POUR ADMINISTRER DES INHIBITEURS DE SIGNALISATION DE LA VOIE WNT AU MOYEN DE L'ÉTAT DE MUTATION RNF43 | Entry into regional phase | 29.09.2014 | National basic fee paid | 29.09.2014 | Designation fee(s) paid | 29.09.2014 | Examination fee paid | Examination procedure | 29.09.2014 | Examination requested [2015/02] | 10.04.2015 | Amendment by applicant (claims and/or description) | 22.02.2016 | Despatch of a communication from the examining division (Time limit: M04) | 21.06.2016 | Reply to a communication from the examining division | 04.11.2016 | Despatch of a communication from the examining division (Time limit: M04) | 01.12.2016 | Reply to a communication from the examining division | 01.03.2017 | Despatch of a communication from the examining division (Time limit: M04) | 14.06.2017 | Reply to a communication from the examining division | 11.07.2017 | Observations by third parties | 06.10.2017 | Despatch of a communication from the examining division (Time limit: M06) | 16.05.2018 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 23.07.2018 | Reply to a communication from the examining division | 08.10.2018 | Despatch of a communication from the examining division (Time limit: M06) | 23.04.2019 | Reply to a communication from the examining division | 14.05.2019 | Observations by third parties | 02.10.2019 | Communication of intention to grant the patent | 28.01.2020 | Fee for grant paid | 28.01.2020 | Fee for publishing/printing paid | 28.01.2020 | Receipt of the translation of the claim(s) | Divisional application(s) | EP20154250.3 / EP3693476 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 22.02.2016 | Opposition(s) | Opponent(s) | 01
15.12.2020
16.12.2021
WITHDRAWN Boehringer Ingelheim RCV GmbH & Co KG / Boehringer Ingelheim International GmbH Dr. Boehringer-Gasse 5-11 / Binger Strasse 173 AT-1121 Wien / DE-55216 Ingelheim am Rhein / AT Opponent's representative D Young & Co LLP 3 Noble Street London EC2V 7BQ / GB | [N/P] |
Former [2022/03] | |||
Opponent(s) | 01
15.12.2020
16.12.2021
WITHDRAWN Boehringer Ingelheim RCV GmbH & Co KG / Boehringer Ingelheim International GmbH Dr. Boehringer-Gasse 5-11 / Binger Strasse 173 AT-1121 Wien / DE-55216 Ingelheim am Rhein / AT Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB | ||
Former [2021/03] | |||
Opponent(s) | 01
15.12.2020
Boehringer Ingelheim RCV GmbH & Co KG / Boehringer Ingelheim International GmbH Dr. Boehringer-Gasse 5-11 / Binger Strasse 173 AT-1121 Wien / DE-55216 Ingelheim am Rhein / AT Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB | 28.01.2021 | Invitation to proprietor to file observations on the notice of opposition | 07.06.2021 | Reply of patent proprietor to notice(s) of opposition | 20.01.2022 | Despatch of communication that the opposition procedure will be closed | 30.01.2022 | Legal effect of closure of opposition procedure [2022/24] | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 23.04.2019 | Request for further processing filed | 23.04.2019 | Full payment received (date of receipt of payment) Request granted | 08.05.2019 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the examination report | 23.07.2018 | Request for further processing filed | 23.07.2018 | Full payment received (date of receipt of payment) Request granted | 02.08.2018 | Decision despatched | Fees paid | Renewal fee | 11.02.2015 | Renewal fee patent year 03 | 10.02.2016 | Renewal fee patent year 04 | 10.02.2017 | Renewal fee patent year 05 | 14.02.2018 | Renewal fee patent year 06 | 13.02.2019 | Renewal fee patent year 07 | 13.02.2020 | Renewal fee patent year 08 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 22.02.2013 | AT | 25.03.2020 | CY | 25.03.2020 | CZ | 25.03.2020 | DK | 25.03.2020 | EE | 25.03.2020 | FI | 25.03.2020 | HR | 25.03.2020 | LT | 25.03.2020 | LV | 25.03.2020 | MC | 25.03.2020 | MK | 25.03.2020 | NL | 25.03.2020 | PL | 25.03.2020 | RO | 25.03.2020 | RS | 25.03.2020 | SE | 25.03.2020 | SI | 25.03.2020 | SK | 25.03.2020 | SM | 25.03.2020 | BG | 25.06.2020 | NO | 25.06.2020 | GR | 26.06.2020 | IS | 25.07.2020 | PT | 18.08.2020 | IE | 22.02.2021 | LU | 22.02.2021 | BE | 28.02.2021 | CH | 28.02.2021 | LI | 28.02.2021 | [2024/22] |
Former [2023/30] | HU | 22.02.2013 | |
AT | 25.03.2020 | ||
CY | 25.03.2020 | ||
CZ | 25.03.2020 | ||
DK | 25.03.2020 | ||
EE | 25.03.2020 | ||
FI | 25.03.2020 | ||
HR | 25.03.2020 | ||
LT | 25.03.2020 | ||
LV | 25.03.2020 | ||
MC | 25.03.2020 | ||
NL | 25.03.2020 | ||
PL | 25.03.2020 | ||
RO | 25.03.2020 | ||
RS | 25.03.2020 | ||
SE | 25.03.2020 | ||
SI | 25.03.2020 | ||
SK | 25.03.2020 | ||
SM | 25.03.2020 | ||
BG | 25.06.2020 | ||
NO | 25.06.2020 | ||
GR | 26.06.2020 | ||
IS | 25.07.2020 | ||
PT | 18.08.2020 | ||
IE | 22.02.2021 | ||
LU | 22.02.2021 | ||
BE | 28.02.2021 | ||
CH | 28.02.2021 | ||
LI | 28.02.2021 | ||
Former [2023/27] | HU | 22.02.2013 | |
AT | 25.03.2020 | ||
CZ | 25.03.2020 | ||
DK | 25.03.2020 | ||
EE | 25.03.2020 | ||
FI | 25.03.2020 | ||
HR | 25.03.2020 | ||
LT | 25.03.2020 | ||
LV | 25.03.2020 | ||
MC | 25.03.2020 | ||
NL | 25.03.2020 | ||
PL | 25.03.2020 | ||
RO | 25.03.2020 | ||
RS | 25.03.2020 | ||
SE | 25.03.2020 | ||
SI | 25.03.2020 | ||
SK | 25.03.2020 | ||
SM | 25.03.2020 | ||
BG | 25.06.2020 | ||
NO | 25.06.2020 | ||
GR | 26.06.2020 | ||
IS | 25.07.2020 | ||
PT | 18.08.2020 | ||
IE | 22.02.2021 | ||
LU | 22.02.2021 | ||
BE | 28.02.2021 | ||
CH | 28.02.2021 | ||
LI | 28.02.2021 | ||
Former [2022/33] | AT | 25.03.2020 | |
CZ | 25.03.2020 | ||
DK | 25.03.2020 | ||
EE | 25.03.2020 | ||
FI | 25.03.2020 | ||
HR | 25.03.2020 | ||
LT | 25.03.2020 | ||
LV | 25.03.2020 | ||
MC | 25.03.2020 | ||
NL | 25.03.2020 | ||
PL | 25.03.2020 | ||
RO | 25.03.2020 | ||
RS | 25.03.2020 | ||
SE | 25.03.2020 | ||
SI | 25.03.2020 | ||
SK | 25.03.2020 | ||
SM | 25.03.2020 | ||
BG | 25.06.2020 | ||
NO | 25.06.2020 | ||
GR | 26.06.2020 | ||
IS | 25.07.2020 | ||
PT | 18.08.2020 | ||
IE | 22.02.2021 | ||
LU | 22.02.2021 | ||
BE | 28.02.2021 | ||
CH | 28.02.2021 | ||
LI | 28.02.2021 | ||
Former [2022/07] | AT | 25.03.2020 | |
CZ | 25.03.2020 | ||
DK | 25.03.2020 | ||
EE | 25.03.2020 | ||
FI | 25.03.2020 | ||
HR | 25.03.2020 | ||
LT | 25.03.2020 | ||
LV | 25.03.2020 | ||
MC | 25.03.2020 | ||
NL | 25.03.2020 | ||
PL | 25.03.2020 | ||
RO | 25.03.2020 | ||
RS | 25.03.2020 | ||
SE | 25.03.2020 | ||
SI | 25.03.2020 | ||
SK | 25.03.2020 | ||
SM | 25.03.2020 | ||
BG | 25.06.2020 | ||
NO | 25.06.2020 | ||
GR | 26.06.2020 | ||
IS | 25.07.2020 | ||
PT | 18.08.2020 | ||
IE | 22.02.2021 | ||
LU | 22.02.2021 | ||
CH | 28.02.2021 | ||
LI | 28.02.2021 | ||
Former [2021/47] | AT | 25.03.2020 | |
CZ | 25.03.2020 | ||
DK | 25.03.2020 | ||
EE | 25.03.2020 | ||
FI | 25.03.2020 | ||
HR | 25.03.2020 | ||
LT | 25.03.2020 | ||
LV | 25.03.2020 | ||
MC | 25.03.2020 | ||
NL | 25.03.2020 | ||
PL | 25.03.2020 | ||
RO | 25.03.2020 | ||
RS | 25.03.2020 | ||
SE | 25.03.2020 | ||
SI | 25.03.2020 | ||
SK | 25.03.2020 | ||
SM | 25.03.2020 | ||
BG | 25.06.2020 | ||
NO | 25.06.2020 | ||
GR | 26.06.2020 | ||
IS | 25.07.2020 | ||
PT | 18.08.2020 | ||
LU | 22.02.2021 | ||
CH | 28.02.2021 | ||
LI | 28.02.2021 | ||
Former [2021/41] | AT | 25.03.2020 | |
CZ | 25.03.2020 | ||
DK | 25.03.2020 | ||
EE | 25.03.2020 | ||
FI | 25.03.2020 | ||
HR | 25.03.2020 | ||
LT | 25.03.2020 | ||
LV | 25.03.2020 | ||
MC | 25.03.2020 | ||
NL | 25.03.2020 | ||
PL | 25.03.2020 | ||
RO | 25.03.2020 | ||
RS | 25.03.2020 | ||
SE | 25.03.2020 | ||
SI | 25.03.2020 | ||
SK | 25.03.2020 | ||
SM | 25.03.2020 | ||
BG | 25.06.2020 | ||
NO | 25.06.2020 | ||
GR | 26.06.2020 | ||
IS | 25.07.2020 | ||
PT | 18.08.2020 | ||
Former [2021/24] | AT | 25.03.2020 | |
CZ | 25.03.2020 | ||
DK | 25.03.2020 | ||
EE | 25.03.2020 | ||
FI | 25.03.2020 | ||
HR | 25.03.2020 | ||
LT | 25.03.2020 | ||
LV | 25.03.2020 | ||
NL | 25.03.2020 | ||
PL | 25.03.2020 | ||
RO | 25.03.2020 | ||
RS | 25.03.2020 | ||
SE | 25.03.2020 | ||
SI | 25.03.2020 | ||
SK | 25.03.2020 | ||
SM | 25.03.2020 | ||
BG | 25.06.2020 | ||
NO | 25.06.2020 | ||
GR | 26.06.2020 | ||
IS | 25.07.2020 | ||
PT | 18.08.2020 | ||
Former [2021/11] | AT | 25.03.2020 | |
CZ | 25.03.2020 | ||
DK | 25.03.2020 | ||
EE | 25.03.2020 | ||
FI | 25.03.2020 | ||
HR | 25.03.2020 | ||
LT | 25.03.2020 | ||
LV | 25.03.2020 | ||
NL | 25.03.2020 | ||
PL | 25.03.2020 | ||
RO | 25.03.2020 | ||
RS | 25.03.2020 | ||
SE | 25.03.2020 | ||
SK | 25.03.2020 | ||
SM | 25.03.2020 | ||
BG | 25.06.2020 | ||
NO | 25.06.2020 | ||
GR | 26.06.2020 | ||
IS | 25.07.2020 | ||
PT | 18.08.2020 | ||
Former [2021/08] | CZ | 25.03.2020 | |
DK | 25.03.2020 | ||
EE | 25.03.2020 | ||
FI | 25.03.2020 | ||
HR | 25.03.2020 | ||
LT | 25.03.2020 | ||
LV | 25.03.2020 | ||
NL | 25.03.2020 | ||
RO | 25.03.2020 | ||
RS | 25.03.2020 | ||
SE | 25.03.2020 | ||
SK | 25.03.2020 | ||
SM | 25.03.2020 | ||
BG | 25.06.2020 | ||
NO | 25.06.2020 | ||
GR | 26.06.2020 | ||
IS | 25.07.2020 | ||
PT | 18.08.2020 | ||
Former [2020/50] | CZ | 25.03.2020 | |
EE | 25.03.2020 | ||
FI | 25.03.2020 | ||
HR | 25.03.2020 | ||
LT | 25.03.2020 | ||
LV | 25.03.2020 | ||
NL | 25.03.2020 | ||
RO | 25.03.2020 | ||
RS | 25.03.2020 | ||
SE | 25.03.2020 | ||
SK | 25.03.2020 | ||
SM | 25.03.2020 | ||
BG | 25.06.2020 | ||
NO | 25.06.2020 | ||
GR | 26.06.2020 | ||
IS | 25.07.2020 | ||
PT | 18.08.2020 | ||
Former [2020/49] | CZ | 25.03.2020 | |
FI | 25.03.2020 | ||
HR | 25.03.2020 | ||
LT | 25.03.2020 | ||
LV | 25.03.2020 | ||
NL | 25.03.2020 | ||
RO | 25.03.2020 | ||
RS | 25.03.2020 | ||
SE | 25.03.2020 | ||
SK | 25.03.2020 | ||
SM | 25.03.2020 | ||
BG | 25.06.2020 | ||
NO | 25.06.2020 | ||
GR | 26.06.2020 | ||
IS | 25.07.2020 | ||
PT | 18.08.2020 | ||
Former [2020/48] | FI | 25.03.2020 | |
HR | 25.03.2020 | ||
LT | 25.03.2020 | ||
LV | 25.03.2020 | ||
NL | 25.03.2020 | ||
RO | 25.03.2020 | ||
RS | 25.03.2020 | ||
SE | 25.03.2020 | ||
SM | 25.03.2020 | ||
BG | 25.06.2020 | ||
NO | 25.06.2020 | ||
GR | 26.06.2020 | ||
IS | 25.07.2020 | ||
PT | 18.08.2020 | ||
Former [2020/47] | FI | 25.03.2020 | |
HR | 25.03.2020 | ||
LT | 25.03.2020 | ||
LV | 25.03.2020 | ||
NL | 25.03.2020 | ||
RS | 25.03.2020 | ||
SE | 25.03.2020 | ||
BG | 25.06.2020 | ||
NO | 25.06.2020 | ||
GR | 26.06.2020 | ||
IS | 25.07.2020 | ||
Former [2020/46] | FI | 25.03.2020 | |
HR | 25.03.2020 | ||
LV | 25.03.2020 | ||
NL | 25.03.2020 | ||
RS | 25.03.2020 | ||
SE | 25.03.2020 | ||
BG | 25.06.2020 | ||
NO | 25.06.2020 | ||
GR | 26.06.2020 | ||
IS | 25.07.2020 | ||
Former [2020/45] | FI | 25.03.2020 | |
HR | 25.03.2020 | ||
LV | 25.03.2020 | ||
NL | 25.03.2020 | ||
RS | 25.03.2020 | ||
SE | 25.03.2020 | ||
BG | 25.06.2020 | ||
NO | 25.06.2020 | ||
GR | 26.06.2020 | ||
Former [2020/39] | FI | 25.03.2020 | |
HR | 25.03.2020 | ||
LV | 25.03.2020 | ||
RS | 25.03.2020 | ||
SE | 25.03.2020 | ||
BG | 25.06.2020 | ||
NO | 25.06.2020 | ||
GR | 26.06.2020 | ||
Former [2020/38] | FI | 25.03.2020 | |
HR | 25.03.2020 | ||
LV | 25.03.2020 | ||
RS | 25.03.2020 | ||
SE | 25.03.2020 | ||
NO | 25.06.2020 | ||
GR | 26.06.2020 | ||
Former [2020/37] | FI | 25.03.2020 | |
HR | 25.03.2020 | ||
LV | 25.03.2020 | ||
RS | 25.03.2020 | ||
SE | 25.03.2020 | ||
NO | 25.06.2020 | ||
Former [2020/35] | FI | 25.03.2020 | |
NO | 25.06.2020 | Cited in | International search | [Y]WO2004032838 (UNIV CALIFORNIA [US], et al) [Y] 1,2,9-15,26-30 * examples 2, 5; claim 24 *; | [IY]WO2006017318 (UNIV CALIFORNIA [US], et al) [I] 1,4,5,7,26-30 * example 12; claims 35, 40, 41, 43 * [Y] 1,2,9-15,26-30; | [Y]WO2011004379 (TEL HASHOMER MEDICAL RES INFRASTRUCTURE & SERVICES LTD [IL], et al) [Y] 1,2,9-15,26-30 * example 5; claim 5 *; | [XI]EP2275544 (ONCOTHERAPY SCIENCE INC [JP]) [X] 16,18,20,24,25 * paragraphs [0194] , [ 245] , [ 246]; sequence 6 * [I] 17,22; | [I] - J. LIU ET AL, "PD08-11: Targeting Porcupine, a Critical Node for Wnt Signalling in Cancer.", CANCER RESEARCH, (20111215), vol. 71, no. 24 Supplement, doi:10.1158/0008-5472.SABCS11-PD08-11, ISSN 0008-5472, pages PD08 - 11, XP055061279 [I] 26-30 * the whole document * DOI: http://dx.doi.org/10.1158/0008-5472.SABCS11-PD08-11 | [XP] - HUAI-XIANG HAO ET AL, "ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner", NATURE, (20120429), vol. 485, no. 7397, doi:10.1038/nature11019, ISSN 0028-0836, pages 195 - 200, XP055061275 [XP] 1-30 * the whole document * DOI: http://dx.doi.org/10.1038/nature11019 | [XP] - BON-KYOUNG KOO ET AL, "Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors", NATURE, (20120815), vol. 488, no. 7413, doi:10.1038/nature11308, ISSN 0028-0836, pages 665 - 669, XP055061276 [XP] 1-30 * the whole document * DOI: http://dx.doi.org/10.1038/nature11308 | by applicant | WO03024392 | US7425612 | US7718364 | WO2010101849 | EP1487877 | US8093011 | - NUSSE R, CELL RESEARCH, (2005), vol. 15, no. 1, pages 28 - 32 | - MCDONALD BT ET AL., DEVELOPMENTAL CELL, (2009), vol. 17, no. 1, pages 9 - 26 | - HAO HX ET AL., NATURE, (2012), vol. 485, no. 7397, pages 195 - 200 | - SUGIURA T ET AL., EXP. CELL RES., (2008), vol. 314, no. 7, pages 1519 - 28 | - MATTHAEI H ET AL., ANN. SURG. ONCOL., (2011), vol. 18, no. 12, pages 3493 - 9 | - LUEBKE AM ET AL., PANCREATOLOGY, (2012), vol. 12, no. 1, pages 16 - 22 | - HEZEL AF, GENES DEV., (2006), vol. 20, no. 10 | - WELLS JM, BMC DEV. BIOL., (2007), vol. 7, page 4 | - HEISER PW ET AL., DEVELOPMENT, (2006), vol. 133, no. 10, pages 2023 - 32 | - MORRIS JP ET AL., NAT. REV. CANCER, (2010), vol. 10, no. 10, pages 683 - 95 | - PASCA DI MAGLIANO M ET AL., PLOS ONE, (2007), vol. 2, no. 11, page E1155 | - WANG L ET AL., CANCER SCI., (2009), vol. 101, no. 3, pages 700 - 6 | - FURUKAWA T ET AL., SCI. REP., (2011), vol. 1, page 161 | - WU J ET AL., PROC. NATL. ACAD. SCI. USA, (2011), vol. 108, no. 52, pages 21188 - 93 | - WU J ET AL., PROC. NATL. ACAD. SCI., (2011), vol. 108, page 2188 | - KOO BK ET AL., NATURE, (2012), vol. 488, no. 7413, pages 665 - 9 | - LOGAN CY; NUSSE R, ANNU. REV. CELL. DEV. BIOL., (2004), vol. 20, pages 781 - 810 | - CLEVERS H, CELL, (2006), vol. 127, no. 3, pages 469 - 80 | - MACDONALD BT ET AL., DEV. CELL, (2009), vol. 17, no. 1, pages 9 - 26 | - ETTENBERG S ET AL., PROC. NATL. ACAD. SCI. USA, (2010), vol. 107, no. 35, pages 15473 - 8 | - GURNEY A ET AL., PROC. NATL. ACAD. SCI. USA, (2012), vol. 109, no. 29, pages 11717 - 22 | - CHEN B ET AL., NAT. CHEM. BIOL., (2009), vol. 5, no. 2, pages 100 - 7 | - LASKO ET AL., ANNU. REV. GENET., (1991), vol. 25, pages 281 - 314 | - VOGELSTEIN ET AL., NEW ENGL. J. MED., (1988), vol. 319, no. 9, pages 525 - 532 | - FEARON ET AL., CELL, (1990), vol. 61, pages 759 - 767 | - FRIEND ET AL., NATURE, (1986), vol. 323, pages 643 - 646 | - CALL ET AL., CELL, (1990), vol. 60, pages 509 - 520 | - KINZLER ET AL., SCIENCE, (1991), vol. 253, pages 661 - 665 | - BAKER ET AL., SCIENCE, (1989), vol. 244, pages 217 - 221 | - THERASSE P. ET AL., J. NATL. CANCER INST., (2000), vol. 92, no. 3, pages 205 - 216 | - THERASSE P ET AL., J. NATL. CANCER INST., (2000), vol. 92, no. 3, pages 205 - 216 | - ROGAN P ET AL., GENOME RES., (2001), vol. 11, no. 6, pages 1086 - 1094 | - MEINKOTH ET AL., ANAL. BIOCHEM., (1984), vol. 138, pages 267 - 284 | - SAMBROOK ET AL., Molecular Cloning: A Laboratory Manual, COLD SPRING HARBOR LABS PRESS, (1989), pages 9.31 - 9.62 | - CHEN B ET AL., NATURE CHEM. BIOL, (2009), vol. 5, pages 100 - 107 | - HUANG SM ET AL., NATURE, (2009), vol. 461, no. 7264, pages 614 - 20 | - DEALMEIDA VI ET AL., CANCER RES., (2007), vol. 67, no. 11, pages 5371 - 9 | - HAO H-X ET AL., NATURE, (2012), vol. 485, no. 7397, pages 195 - 200 | - KOO BK, NATURE, (2012), vol. 488, no. 7413, pages 665 - 9 | - SCHOLER-DAHIREL A ET AL., PROC. NATL. ACAD. SCI. USA, (2011), vol. 108, no. 41, pages 17135 - 40 | Opposition | WO2013011479 | WO2013054307 | EP2820151 | WO2017093478 | - SATO et al., "MAINTENANCE OF PLURIPOTENCY IN HUMAN AND MOUSE EMBRYONIC STEM CELLS THROUGH ACTIVATION OF WNT SIGNALING BY A PHARMACOLOGICAL GSK-3-SPECIFIC INHIBITOR", Nature Medicine, (20040000), vol. 10, no. 1, pages 55 - 63, XP002380572 | - RING et al., "Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo", Diabetes, (20030000), vol. 52, pages 588 - 595, XP002305100 DOI: http://dx.doi.org/10.2337/diabetes.52.3.588 | - Huai-Xiang Hao; Yang Xie; Yue Zhang; Olga Charlat; Emma Oster; Monika Avello; Hong Lei; Craig Mickanin; Dong Liu; Heinz Ruffner; Xiaohong Mao; Qicheng Ma; Raffaella Zamponi; Tewis Bouwmeester; Peter M Finan; Marc W Kirschner; Jeffery A Porter; Fabrizio C Serluca; Feng Cong, "ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner", Nature, (20120000), vol. 485, no. 7397, pages 195 - 200, XP002706010 DOI: http://dx.doi.org/10.1038/NATURE11019 | - Bon-Kyoung Koo; Maureen Spit; Ingrid Jordens; Teck Y Low; Daniel E Stange; Marc van de Wetering; Johan H van Es; Shabaz Mohammed; Albert J R Heck; Madelon M Maurice; Hans Clevers, "Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors", Nature, (20120000), vol. 488, pages 665 - 669, XP002696011 DOI: http://dx.doi.org/10.1038/nature11308 | - Dong Guo, Siu Yuen, Wai Tsui, Annie Chan, Tsun Chan and Suet Leung, "Expression of wnt signaling target genes in colorectal cancer progression", AACR annual meeting, (20070000), pages 1 - 3, XP055783273 | - IVANOV et al., "Identifying candidate colon cancer tumor suppressor genes using inhibition of nonsense-mediated mRNA decay in colon cancer cells", Oncogene, (20070000), vol. 26, pages 2873 - 2884, XP055783277 | - Wu J; Jiao Y; Dal Molin M; Maitra A; De Wilde R F; Wood L D; Eshleman J R; Goggins M G; Wolfgang C L; Canto M I; Schulick R D; Edil B H; Choti M A; Adsay V; Klimstra D S; Offerhaus G J A; Klein A P; Kopelovich L; Carter H; Karchin R; Allen P J; Schmidt C M; Naito Y; Diaz L A; Kinzler K W; Papadopoulos N; Hruban R H; Vogelstein B, "Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways", PNAS, (20110000), vol. 108, no. 52, pages 21188 - 21193, XP055069412 DOI: http://dx.doi.org/10.1073/pnas.1118046108 | - Baozhi Chen; Michael E Dodge; Wei Tang; Jianming Lu; Zhiqiang Ma; Chih-Wei Fan; Shuguang Wei; Wayne Hao; Jessica Kilgore; Noelle S Williams; Michael G Roth; James F Amatruda; Chuo Chen; Lawrence Lum, "Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer", Nat Chem Biol, (20090000), vol. 5, no. 2, pages 100 - 107, XP055295218 DOI: http://dx.doi.org/10.1038/nchembio.137 | - Liu J; Pan S; Sun F; Kasibhatla S; Schuller A; Li A; Li C; Cui X; Wang T; Villarroel M; Mclaughlin M; Sellers W; Boral A; Harris J, "PD08-11: Targeting Porcupine, a Critical Node for Wnt Signalling in Cancer", Cancer Research, (20110000), vol. 71, no. 24, page PD08-11, XP055061279 DOI: http://dx.doi.org/10.1158/0008-5472.SABCS11-PD08-11 | - NUSSE R., "Wnt signaling in disease and in development", Cell Research, (20050000), vol. 15, no. 1, pages 28 - 32, XP055783283 | - Aguilera O; Fraga M F; Ballestar E; Paz M F; Herranz M; Espada J; García J M; Muñoz A; Esteller M; González-Sancho J M, "Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer", Oncogene, (20060000), vol. 25, no. 29, pages 4116 - 4121, XP002679453 DOI: http://dx.doi.org/10.1038/SJ.ONC.1209439 | - Akiko Mukai, Miki Yamamoto-Hino, Wakae Awano, Wakako Watanabe, Masayuki Komada, Satoshi Goto, "Balanced ubiquitylation and deubiquitylation of frizzled regulate cellular responsiveness to Wg/Wnt", The EMBO Journal, (20100000), vol. 29, no. 13, pages 2114 - 2125, XP055783291 | - CAIRO et al., "Hepatic Stem-like Phenotype and Interplay of Wnt/beta-Catenin and Myc Signaling in Aggressive Childhood Liver Cancer", Cancer Cell, (20080000), vol. 14, pages 471 - 484, XP002508978 DOI: http://dx.doi.org/10.1016/J.CCR.2008.11.002 | - Daniel Bottomly, Sydney L. Kyler, Shannon K. McWeeney, and Gregory S. Yochum, "Identification of β-catenin binding regions in colon cancer cells using ChIP-Seq", Nucleic Acids Research, (20100000), vol. 38, no. 17, pages 5735 - 5745, XP055783300 | - Anonymous, "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands", ClinicalTrials.gov, (20110500), pages 1 - 9, XP002780915 | - Toru Furukawa; Yuko Kuboki; Etsuko Tanji; Shoko Yoshida; Takashi Hatori; Masakazu Yamamoto; Noriyuki Shibata; Kyoko Shimizu; Naoyuki Kamatani; and Keiko Shiratori, "Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas", Scientific Reports, (20110000), vol. 1, no. 161, pages 1 - 7, XP002733929 DOI: http://dx.doi.org/10.1038/srep00161 | - Anonymous, "Small molecules in Wnt signalling", the Wnt homepage, (20180123), page 1, URL: https://web.stanford.edu/group/nusselab/cgi/bin/wnt/smallmolecules, XP055783318 | - Jiang X; H-X Hao; Growney J D; Woolfenden S; Bottiglio C; Ng N; Lu B; Hsieh M H; Bagdasarian L; Meyer R; Smith T R; Avello M; Charlat O; Xie Y; Porter J A; Pan S; Liu J; Mclaughlin M E; Cong F, "Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma", PNAS, (20130000), vol. 110, no. 31, pages 12649 - 12654, XP055200712 DOI: http://dx.doi.org/10.1073/pnas.1307218110 | - Jianghua Tu , Soohyun Park , Wangsheng Yu , Sheng Zhang , Ling Wu , Kendra Carmon , Qingyun J Liu, "The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis", Sci Rep, (20190000), vol. 9, no. 18557, pages 1 - 12, XP055783323 | - Li Shan; Lavrijsen Marla; Bakker Aron; Magierowski Marcin; Magierowska Katarzyna; Liu Pengyu; Wang Wenhui; Peppelenbosch Maikel P; Smits Ron, "Commonly observedmutations retain functionality in attenuating Wnt/β-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers", Oncogene, (20200000), vol. 39, pages 3458 - 3472, XP037098180 DOI: http://dx.doi.org/10.1038/s41388-020-1232-5 | - Kyoung-Sub Song , Kaipeng Jing, Jong-Seok Kim, Eun-Jin Yun, Soyeon Shin, Kang-Sik Seo, Ji-Hoon Park, Jun-Young Heo, Jing X Kang, Kwang-Sun Suh, Tong Wu, Jong-Il Park, Gi-Ryang Kweon, Wan-Hee Yoon, Byung-Doo Hwang, Kyu Lim, "Omeda-3-polyunsaturated fatty acids suppress pancreatic cancer cell growth in vitro and in vivo via downregulation of Wnt/Beta-Catenin Signaling", Pancreatology, (20110000), vol. 11, pages 574 - 584, XP055783337 |